On April 21, the reporter learned from Novo Nordisk that the National Drug Administration of China (NMPA) approved the update of the instructions of Novo (weight-reduced version of smegerutide 2.4mg). This update is based on the main results of SELECT (Smegerutide Cardiovascular Outcomes Trial in Overweight or Obese Patients): In overweight or obese adult patients with diagnosed cardiovascular disease without diabetes, Novo reduced the risk of major adverse cardiovascular events (MACE, including...